Yohei Doi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6998654/publications.pdf

Version: 2024-02-01

329 papers	24,595 citations	7551 77 h-index	9073 144 g-index
339 all docs	339 docs citations	339 times ranked	19538 citing authors

#	Article	IF	Citations
1	Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infectious Diseases, The, 2016, 16, 161-168.	4.6	4,130
2	The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 2017, 8, 460-469.	1.8	613
3	16S Ribosomal RNA Methylation: Emerging Resistance Mechanism against Aminoglycosides. Clinical Infectious Diseases, 2007, 45, 88-94.	2.9	587
4	Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 2018, 66, 163-171.	2.9	485
5	Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrobial Agents and Chemotherapy, 2012, 56, 2108-2113.	1.4	468
6	Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infectious Diseases, The, 2021, 21, 226-240.	4.6	411
7	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	4.6	367
8	Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.. Clinical Infectious Diseases, 2016, 63, 1615-1618.	2.9	362
9	Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, 2019, 69, S565-S575.	2.9	361
10	Colistin and its role in the Era of antibiotic resistance: an extended review (2000â€“2019). Emerging Microbes and Infections, 2020, 9, 868-885.	3.0	349
11	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	347
12	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla _{KPC-3} Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	334
13	Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance. Clinical Infectious Diseases, 2015, 60, 1295-1303.	2.9	315
14	Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. New England Journal of Medicine, 2018, 379, 236-249.	13.9	304
15	PCR Typing of Genetic Determinants for Metallo-Â-Lactamases and Integrases Carried by Gram-Negative Bacteria Isolated in Japan, with Focus on the Class 3 Integron. Journal of Clinical Microbiology, 2003, 41, 5407-5413.	1.8	298
16	Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1 -positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infectious Diseases, The, 2017, 17, 390-399.	4.6	298
17	Community-Associated Extended-Spectrum Î²-Lactamaseâ€“Producing Escherichia coli Infection in the United States. Clinical Infectious Diseases, 2013, 56, 641-648.	2.9	276
18	Aminoglycoside Resistance. Infectious Disease Clinics of North America, 2016, 30, 523-537.	1.9	252

#	Article	IF	Citations
19	Natural History of Asymptomatic SARS-CoV-2 Infection. New England Journal of Medicine, 2020, 383, 885-886.	13.9	247
20	Acinetobacter baumannii: Evolution of Antimicrobial Resistanceâ€"Treatment Options. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 085-098.	0.8	233
21	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clinical Infectious Diseases, 2017, 65, 110-120.	2.9	224
22	Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infectious Diseases, The, 2016, 16, 288-289.	4.6	214
23	New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	208
24	Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa. Lancet, The, 2003, 362, 1888-1893.	6.3	199
25	The ecology of extended-spectrum Î²-lactamases (ESBLs) in the developed world. Journal of Travel Medicine, 2017, 24, S44-S51.	1.4	182
26	A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	177
27	Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections. Drugs, 2014, 74, 1315-1333.	4.9	174
28	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741.	4.6	174
29	Carbapenemase-Producing Enterobacteriaceae. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 074-084.	0.8	173
30	Plasmid-Mediated 16S rRNA Methylase in Serratia marcescens Conferring High-Level Resistance to Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2004, 48, 491-496.	1.4	166
31	Carbapenem-Resistant Enterobacteriaceae. Clinics in Laboratory Medicine, 2017, 37, 303-315.	0.7	161
32	CTX-M-15-D-ST648 Escherichia coli from companion animals and horses: another pandemic clone combining multiresistance and extraintestinal virulence?. Journal of Antimicrobial Chemotherapy, 2014, 69, 1224-1230.	1.3	160
33	Unique Structural Modifications Are Present in the Lipopolysaccharide from Colistin-Resistant Strains of Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2013, 57, 4831-4840.	1.4	159
34	Pseudomonas aeruginosa utilizes host polyunsaturated phosphatidylethanolamines to trigger theft-ferroptosis in bronchial epithelium. Journal of Clinical Investigation, 2018, 128, 4639-4653.	3.9	159
35	Predatory Bacteria: A Potential Ally against Multidrug-Resistant Gram-Negative Pathogens. PLoS ONE, 2013, 8, e63397.	1.1	159
36	Dissemination of the mcr-1 colistin resistance gene. Lancet Infectious Diseases, The, 2016, 16, 292-293.	4.6	151

#	Article	IF	Citations
37	Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clinical Infectious Diseases, 2017, 64, ciw805.	2.9	150
38	A Primer on AmpC Î²-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clinical Infectious Diseases, 2019, 69, 1446-1455.	2.9	148
39	Normal Development of Mice and Unimpaired Cell Adhesion/Cell Motility/Actin-based Cytoskeleton without Compensatory Up-regulation of Ezrin or Radixin in Moesin Gene Knockout. Journal of Biological Chemistry, 1999, 274, 2315-2321.	1.6	147
40	Rational Design of Engineered Cationic Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan, and Their Activity against Multidrug-Resistant Pathogens. Antimicrobial Agents and Chemotherapy, 2013, 57, 2511-2521.	1.4	147
41	Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection. PLoS ONE, 2012, 7, e29446.	1.1	147
42	Practical Methods Using Boronic Acid Compounds for Identification of Class C Î²-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli. Journal of Clinical Microbiology, 2005, 43, 2551-2558.	1.8	145
43	Genetic Basis of Multidrug Resistance in Acinetobacter baumannii Clinical Isolates at a Tertiary Medical Center in Pennsylvania. Antimicrobial Agents and Chemotherapy, 2008, 52, 3837-3843.	1.4	145
44	Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. MBio, 2017, 8, .	1.8	138
45	Extended-spectrum and CMY-type b-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clinical Microbiology and Infection, 2010, 16, 33-38.	2.8	133
46	PCR Classification of CTX-M-Type Î²-Lactamase Genes Identified in Clinically Isolated Gram-Negative Bacilli in Japan. Antimicrobial Agents and Chemotherapy, 2006, 50, 791-795.	1.4	132
47	Colistin-Resistant, Klebsiella pneumoniae Carbapenemase (KPC)-Producing Klebsiella pneumoniae Belonging to the International Epidemic Clone ST258. Clinical Infectious Diseases, 2011, 53, 373-376.	2.9	125
48	Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. Journal of Antimicrobial Chemotherapy, 2012, 67, 1569-1577.	1.3	125
49	Possible Transmission ofmcr-1â€“HarboringEscherichia colibetween Companion Animals and Human. Emerging Infectious Diseases, 2016, 22, 1679-1681.	2.0	125
50	Global Spread of Multiple Aminoglycoside Resistance Genes. Emerging Infectious Diseases, 2005, 11, 951-953.	2.0	124
51	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412.	4.6	122
52	Simple Disk-Based Method for Detection of Klebsiella pneumoniae Carbapenemase-Type Î²-Lactamase by Use of a Boronic Acid Compound. Journal of Clinical Microbiology, 2008, 46, 4083-4086.	1.8	120
53	Molecular Epidemiology of Carbapenem-Nonsusceptible Acinetobacter baumannii in the United States. Journal of Clinical Microbiology, 2011, 49, 3849-3854.	1.8	120
54	A Step Closer to Extreme Drug Resistance (XDR) in Gram-Negative Bacilli. Clinical Infectious Diseases, 2007, 45, 1179-1181.	2.9	119

#	Article	IF	Citations
55	Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania. Antimicrobial Agents and Chemotherapy, 2009, 53, 4733-4739.	1.4	116
56	Clinical Outcomes of Hospital-Acquired Infection with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrobial Agents and Chemotherapy, 2014, 58, 4172-4179.	1.4	115
57	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S30-S35.	2.9	114
58	Engineered Cationic Antimicrobial Peptides To Overcome Multidrug Resistance by ESKAPE Pathogens. Antimicrobial Agents and Chemotherapy, 2015, 59, 1329-1333.	1.4	108
59	Novel Plasmid-Mediated 16S rRNA Methylase, RmtC, Found in a Proteus mirabilis Isolate Demonstrating Extraordinary High-Level Resistance against Various Aminoglycosides. Antimicrobial Agents and Chemotherapy, 2006, 50, 178-184.	1.4	105
60	Extensively Drug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2009, 15, 980-982.	2.0	101
61	Proposal for assignment of allele numbers for mobile colistin resistance (mcr) genes. Journal of Antimicrobial Chemotherapy, 2018, 73, 2625-2630.	1.3	101
62	Coproduction of Novel 16S rRNA Methylase RmtD and Metallo-Î²-Lactamase SPM-1 in a Panresistant Pseudomonas aeruginosa Isolate from Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 852-856.	1.4	99
63	Epidemiology and Molecular Characterization of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae in Transplant Recipients. American Journal of Transplantation, 2013, 13, 2619-2633.	2.6	99
64	Carbapenem-Resistant Klebsiella pneumoniae Strains Exhibit Diversity in Aminoglycoside-Modifying Enzymes, Which Exert Differing Effects on Plazomicin and Other Agents. Antimicrobial Agents and Chemotherapy, 2014, 58, 4443-4451.	1.4	99
65	A novel apoptosis-inducing protein from Helicobacter pylori. Molecular Microbiology, 2003, 47, 443-451.	1.2	97
66	Escherichia coliProducing CTX-M-2 Î²-Lactamase in Cattle, Japan. Emerging Infectious Diseases, 2004, 10, 69-75.	2.0	96
67	Structural Modification of Lipopolysaccharide Conferred by mcr-1 in Gram-Negative ESKAPE Pathogens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	96
68	Fosfomycin: Resurgence of an old companion. Journal of Infection and Chemotherapy, 2016, 22, 273-280.	0.8	95
69	Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clinical Microbiology and Infection, 2016, 22, 513-519.	2.8	95
70	Interspecies Spread ofKlebsiella pneumoniaeCarbapenemase Gene in a Single Patient. Clinical Infectious Diseases, 2009, 49, 1736-1738.	2.9	94
71	Emergence of the Plasmid-Mediated mcr-1 Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2016, 60, 3862-3863.	1.4	92
72	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	1.4	89

#	Article	IF	Citations
73	Mutations of the ompK36 Porin Gene and Promoter Impact Responses of Sequence Type 258, KPC-2-Producing Klebsiella pneumoniae Strains to Doripenem and Doripenem-Colistin. Antimicrobial Agents and Chemotherapy, 2013, 57, 5258-5265.	1.4	87
74	Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. Infection and Chemotherapy, 2014, 46, 149.	1.0	86
75	Synthesis of variously oxidized abietane diterpenes and their antibacterial activities against MRSA and VRE. Bioorganic and Medicinal Chemistry, 2001, 9, 347-356.	1.4	85
76	Dynamics of mcr-1 prevalence and mcr-1-positive Escherichia coli after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing-based molecular epidemiological study. Lancet Microbe, The, 2020, 1, e34-e43.	3.4	85
77	Outer Membrane Protein Changes and Efflux Pump Expression Together May Confer Resistance to Ertapenem in Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 2006, 50, 2833-2835.	1.4	83
78	Coproduction of 16S rRNA Methyltransferase RmtD or RmtG with KPC-2 and CTX-M Group Extended-Spectrum Î²-Lactamases in Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2013, 57, 2397-2400.	1.4	80
79	An â€œUnlikelyâ€•Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	1.8	80
80	Genomic Epidemiology of an Endoscope-Associated Outbreak of Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae. PLoS ONE, 2015, 10, e0144310.	1.1	75
81	Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Science Advances, 2020, 6, eaay6817.	4.7	75
82	Detection of plasmid-mediated class C Î²-lactamases. International Journal of Infectious Diseases, 2007, 11, 191-197.	1.5	71
83	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clinical Infectious Diseases, 2020, 71, 667-671.	2.9	71
84	High prevalence of CTX-M-15-producing Klebsiella pneumoniae among inpatients and outpatients with urinary tract infection in Southern India. Journal of Antimicrobial Chemotherapy, 2008, 61, 1393-1394.	1.3	68
85	High Rates of Human Fecal Carriage of mcr-1â€“Positive Multidrug-Resistant Enterobacteriaceae Emerge in China in Association With Successful Plasmid Families. Clinical Infectious Diseases, 2018, 66, 676-685.	2.9	68
86	High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagnostic Microbiology and Infectious Disease, 2011, 70, 246-252.	0.8	67
87	Emergence of mcr-1 in Raoultella ornithinolytica and Escherichia coli Isolates from Retail Vegetables in China. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	67
88	Risk factors and outcome of extended-spectrum Î²-lactamase-producing Enterobacter cloacae bloodstream infections. International Journal of Antimicrobial Agents, 2011, 37, 26-32.	1.1	66
89	Extended-Spectrum AmpC Cephalosporinase in Acinetobacter baumannii: ADC-56 Confers Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2011, 55, 4922-4925.	1.4	66
90	Nosocomial Spread of Ceftazidime-Resistant Klebsiella pneumoniae Strains Producing a Novel Class A Î²-Lactamase, GES-3, in a Neonatal Intensive Care Unit in Japan. Antimicrobial Agents and Chemotherapy, 2004, 48, 1960-1967.	1.4	64

#	Article	IF	Citations
91	Identification of 16S rRNA Methylase-Producing Acinetobacter baumannii Clinical Strains in North America. Antimicrobial Agents and Chemotherapy, 2007, 51, 4209-4210.	1.4	64
92	Activities of Vancomycin-Containing Regimens against Colistin-Resistant Acinetobacter baumannii Clinical Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 2103-2108.	1.4	64
93	Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A Î²-Lactamase, GES-4, Possessing a Single G170S Substitution in the Î©-Loop. Antimicrobial Agents and Chemotherapy, 2004, 48, 2905-2910.	1.4	63
94	Identification of the ESKAPE pathogens by mass spectrometric analysis of microbial membrane glycolipids. Scientific Reports, 2017, 7, 6403.	1.6	63
95	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused byEnterobacter,CitrobacterorSerratiaspecies: a systematic review with meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 296-306.	1.3	62
96	mcr-1â^'Harboring Salmonella enterica Serovar Typhimurium Sequence Type 34 in Pigs, China. Emerging Infectious Diseases, 2017, 23, 291-295.	2.0	62
97	Whole-Genome Assembly of Klebsiella pneumoniae Coproducing NDM-1 and OXA-232 Carbapenemases Using Single-Molecule, Real-Time Sequencing. Antimicrobial Agents and Chemotherapy, 2014, 58, 5947-5953.	1.4	61
98	Respiratory Microbiome Profiling for Etiologic Diagnosis of Pneumonia in Mechanically Ventilated Patients. Frontiers in Microbiology, 2018, 9, 1413.	1.5	61
99	Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	61
100	Multiclonal Outbreak of Klebsiella pneumoniae Producing Extended-Spectrum Î²-Lactamase CTX-M-2 and Novel Variant CTX-M-59 in a Neonatal Intensive Care Unit in Brazil. Antimicrobial Agents and Chemotherapy, 2008, 52, 1790-1793.	1.4	59
101	Structural modification of LPS in colistin-resistant, KPC-producing Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2017, 72, 3035-3042.	1.3	59
102	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	2.8	58
103	Co-Production of NDM-1 and OXA-232 byKlebsiella pneumoniae. Emerging Infectious Diseases, 2014, 20, 163-165.	2.0	58
104	Genetic Environments of the rmtA Gene in Pseudomonas aeruginosa Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2069-2074.	1.4	56
105	Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime. Clinical Infectious Diseases, 2020, 71, 2713-2716.	2.9	56
106	Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis, 1997, 132, 145-150.	0.4	54
107	Apoptotic Signaling Pathway Activated byHelicobacter pylori Infection and Increase of Apoptosis-Inducing Activity under Serum-Starved Conditions. Infection and Immunity, 2001, 69, 3181-3189.	1.0	54
108	Characterization of a Novel Plasmid-Mediated Cephalosporinase (CMY-9) and Its Genetic Environment in an Escherichia coli Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2002, 46, 2427-2434.	1.4	54

#	Article	IF	Citations
109	Aerosolization of Acinetobacter baumannii in a Trauma ICU*. Critical Care Medicine, 2013, 41, 1915-1918.	0.4	53
110	Features of Infections Due to Klebsiella pneumoniae Carbapenemaseâ€“Producing Escherichia coli: Emergence of Sequence Type 131. Clinical Infectious Diseases, 2012, 55, 224-231.	2.9	52
111	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. Clinical Infectious Diseases, 2020, 70, 1826-1833.	2.9	52
112	Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection. International Journal of Infectious Diseases, 2021, 107, 195-200.	1.5	52
113	Novel 16S rRNA Methyltransferase RmtH Produced by Klebsiella pneumoniae Associated with War-Related Trauma. Antimicrobial Agents and Chemotherapy, 2013, 57, 2413-2416.	1.4	51
114	Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	51
115	Characterization of Porin Expression in Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae Identifies Isolates Most Susceptible to the Combination of Colistin and Carbapenems. Antimicrobial Agents and Chemotherapy, 2013, 57, 2147-2153.	1.4	50
116	Antimicrobial treatment challenges in the era of carbapenem resistance. Diagnostic Microbiology and Infectious Disease, 2019, 94, 413-425.	0.8	50
117	Glutathione-S-transferase FosA6 ofKlebsiella pneumoniaeorigin conferring fosfomycin resistance in ESBL-producingEscherichia coli. Journal of Antimicrobial Chemotherapy, 2016, 71, 2460-2465.	1.3	49
118	High Prevalence of Metallo-Î²-Lactamase and 16S rRNA Methylase Coproduction among Imipenem-Resistant Pseudomonas aeruginosa Isolates in Brazil. Antimicrobial Agents and Chemotherapy, 2007, 51, 3388-3390.	1.4	48
119	Complete Sequence of a Novel IncR-F33:Aâ€“:Bâ€“ Plasmid, pKP1034, Harboring fosA3 , bla _{KPC-2} , bla _{CTX-M-65} , bla _{SHV-12} , and rmtB from an Epidemic Klebsiella pneumoniae Sequence Type 11 Strain in China. Antimicrobial Agents and Chemotherapy, 2016, 60, 1343-1348.	1.4	48
120	Characterization of a Naturally Occurring Class D Î²-Lactamase from Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy, 2008, 52, 1952-1956.	1.4	45
121	Clinical Features and Molecular Epidemiology of CMYâ€Type Î²â€Lactamaseâ€“ProducingEscherichia coli. Clinical Infectious Diseases, 2009, 48, 739-744.	2.9	45
122	Fosfomycin Resistance inEscherichia coli, Pennsylvania, USA. Emerging Infectious Diseases, 2015, 21, 2045-2047.	2.0	45
123	The Rise of Fluoroquinolone-ResistantEscherichia coliin the Community: Scarier Than We Thought. Journal of Infectious Diseases, 2015, 212, 1853-1855.	1.9	45
124	MCR-1-producing Klebsiella pneumoniae outbreak in China. Lancet Infectious Diseases, The, 2017, 17, 577.	4.6	45
125	Spread of Novel Aminoglycoside Resistance Gene aac (6 â€²)- Iad among Acinetobacter Clinical Isolates in Japan. Antimicrobial Agents and Chemotherapy, 2004, 48, 2075-2080.	1.4	44
126	Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum Î²-lactamase belonging to ST410 phylogroup A. International Journal of Antimicrobial Agents, 2011, 37, 365-367.	1.1	44

#	Article	IF	Citations
127	Inhibitor-Sensitive AmpC Î²-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and Cephamycins. Antimicrobial Agents and Chemotherapy, 2004, 48, 2652-2658.	1.4	43
128	Enhancing Resistance to Cephalosporins in Class C Î²-Lactamases: Impact of Gly214Glu in CMY-2. Biochemistry, 2010, 49, 1014-1023.	1.2	43
129	Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. American Journal of Infection Control, 2013, 41, 1249-1252.	1.1	43
130	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	2.9	43
131	Molecular Epidemiology of Ceftriaxone-Nonsusceptible Enterobacterales Isolates in an Academic Medical Center in the United States. Open Forum Infectious Diseases, 2019, 6, ofz353.	0.4	43
132	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2045-2052.	2.9	43
133	Klebsiella pneumoniae ST147 Coproducing NDM-7 Carbapenemase and RmtF 16S rRNA Methyltransferase in Minnesota. Journal of Clinical Microbiology, 2014, 52, 4109-4110.	1.8	42
134	Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy, 2009, 53, 2700-2701.	1.4	41
135	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	1.3	41
136	Phylogenomics of colistin-susceptible and resistant XDR Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2018, 73, 2952-2959.	1.3	41
137	Community-acquired Extended-Spectrum Î²-Lactamase Producers, United States. Emerging Infectious Diseases, 2007, 13, 1121-1123.	2.0	40
138	In Vitro Responses of Acinetobacter baumannii to Two- and Three-Drug Combinations following Exposure to Colistin and Doripenem. Antimicrobial Agents and Chemotherapy, 2014, 58, 1195-1199.	1.4	40
139	Screening for Acinetobacter baumannii Colonization by Use of Sponges. Journal of Clinical Microbiology, 2011, 49, 154-158.	1.8	39
140	The role of horizontal gene transfer in the dissemination of extended-spectrum beta-lactamaseâ€“producing Escherichia coli and Klebsiella pneumoniae isolates in an endemic setting. Diagnostic Microbiology and Infectious Disease, 2012, 74, 34-38.	0.8	39
141	Rapid Microbial Identification and Antibiotic Resistance Detection by Mass Spectrometric Analysis of Membrane Lipids. Analytical Chemistry, 2019, 91, 1286-1294.	3.2	39
142	Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum-Î²-Lactamase-Producing Escherichia coli and the Role of TEM-1 Hyperproduction. Antimicrobial Agents and Chemotherapy, 2011, 55, 495-501.	1.4	38
143	Identification of Diverse OXA-40 Group Carbapenemases, Including a Novel Variant, OXA-160, fromAcinetobacter baumanniiin Pennsylvania. Antimicrobial Agents and Chemotherapy, 2011, 55, 429-432.	1.4	38
144	Clinical characteristics of bacteraemia caused by extended-spectrum Î²-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type Î²-lactamases. Clinical Microbiology and Infection, 2012, 18, 887-893.	2.8	38

#	Article	IF	Citations
145	Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system. Diagnostic Microbiology and Infectious Disease, 2014, 80, 154-158.	0.8	38
146	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-Î²-Lactamase-Producing Enterobacter Species. Antimicrobial Agents and Chemotherapy, 2016, 60, 5208-5214.	1.4	38
147	Acinetobacter baumannii: Association between Environmental Contamination of Patient Rooms and Occupant Status. Infection Control and Hospital Epidemiology, 2013, 34, 517-520.	1.0	37
148	Complete Nucleotide Sequences of bla _{CTX-M} -Harboring IncF Plasmids from Community-Associated Escherichia coli Strains in the United States. Antimicrobial Agents and Chemotherapy, 2015, 59, 3002-3007.	1.4	37
149	Commentary: Outbreak of Colistin-Resistant, Carbapenemase-Producing Klebsiella pneumoniae: Are We at the End of the Road?. Journal of Clinical Microbiology, 2015, 53, 3116-3117.	1.8	37
150	Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 7355-7361.	1.4	37
151	Elimination of Antibiotic Resistant Surgical Implant Biofilms Using an Engineered Cationic Amphipathic Peptide WLBU2. Scientific Reports, 2017, 7, 18098.	1.6	37
152	Aminoglycoside Resistance. Infectious Disease Clinics of North America, 2020, 34, 887-902.	1.9	37
153	Molecular Epidemiology of KPC-Producing Escherichia coli: Occurrence of ST131- fimH30 Subclone Harboring pKpQIL-Like IncFIIk Plasmid. Antimicrobial Agents and Chemotherapy, 2014, 58, 4234-4237.	1.4	36
154	Coproduction of MCR-1 and NDM-1 by Colistin-Resistant Escherichia coli Isolated from a Healthy Individual. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	35
155	Aztreonam Combination Therapy: An Answer to Metallo-Î²-Lactamaseâ€“Producing Gram-Negative Bacteria?. Clinical Infectious Diseases, 2020, 71, 1099-1101.	2.9	35
156	Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens. Frontiers in Microbiology, 2018, 9, 721.	1.5	34
157	Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. Journal of Microbiology, Immunology and Infection, 2019, 52, 796-806.	1.5	34
158	Nomenclature of Plasmid-Mediated 16S rRNA Methylases Responsible for Panaminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 2287-2288.	1.4	33
159	CTX-M-2â€“ProducingSalmonellaTyphimurium Isolated from Pediatric Patients and Poultry in Brazil. Microbial Drug Resistance, 2009, 15, 317-321.	0.9	33
160	Susceptibility of colistin-resistant pathogens to predatory bacteria. Research in Microbiology, 2018, 169, 52-55.	1.0	33
161	Diversity among blaKPC-containing plasmids in Escherichia coli and other bacterial species isolated from the same patients. Scientific Reports, 2018, 8, 10291.	1.6	33
162	Comparative analysis of an IncR plasmid carryingarmA,bla_{DHA-1}andqnrB4fromKlebsiella pneumoniaeST37 isolates. Journal of Antimicrobial Chemotherapy, 2016, 71, 882-886.	1.3	32

#	Article	IF	Citations
163	Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coli. Journal of Clinical Microbiology, 2018, 56, .	1.8	32
164	Clinical and Microbiologic Characteristics of Cephalosporin-Resistant Escherichia coli at Three Centers in the United States. Antimicrobial Agents and Chemotherapy, 2012, 56, 1870-1876.	1.4	31
165	Epidemiology and Clinical Outcomes of Patients with Carbapenem-Resistant Klebsiella pneumoniae Bacteriuria. Antimicrobial Agents and Chemotherapy, 2014, 58, 3100-3104.	1.4	31
166	Carbapenem-Resistant Acinetobacter baumannii: Concomitant Contamination of Air and Environmental Surfaces. Infection Control and Hospital Epidemiology, 2016, 37, 777-781.	1.0	31
167	In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA. Microbiology Spectrum, 2021, 9, e0177921.	1.2	31
168	Reduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates Producing Novel Variants of CMY-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2009, 53, 3159-3161.	1.4	29
169	CD36 Provides Host Protection AgainstKlebsiella pneumoniaeIntrapulmonary Infection by Enhancing Lipopolysaccharide Responsiveness and Macrophage Phagocytosis. Journal of Infectious Diseases, 2016, 214, 1865-1875.	1.9	28
170	Structure and Dynamics of FosA-Mediated Fosfomycin Resistance in Klebsiella pneumoniae and Escherichia coli. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	28
171	Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii. Journal of Antibiotics, 2016, 69, 415-421.	1.0	27
172	Origin of the plasmid-mediated fosfomycin resistance gene fosA3. Journal of Antimicrobial Chemotherapy, 2018, 73, 373-376.	1.3	27
173	Detection of high-risk carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates using volatile molecular profiles. Scientific Reports, 2018, 8, 13297.	1.6	27
174	Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. MBio, 2022, 13, e0275921.	1.8	27
175	Escherichia coli Isolate Coproducing 16S rRNA Methylase and CTX-M-Type Extended-Spectrum Î²-Lactamase Isolated from an Outpatient in the United States. Antimicrobial Agents and Chemotherapy, 2008, 52, 1204-1205.	1.4	26
176	Outcomes of adjunctive therapy with intrathecal or intraventricular administration of colistin for post-neurosurgical meningitis and ventriculitis due to carbapenem-resistant acinetobacter baumannii. International Journal of Antimicrobial Agents, 2018, 51, 646-650.	1.1	26
177	Trends in Antimicrobial-Drug Resistance in Japan. Emerging Infectious Diseases, 2000, 6, 572-575.	2.0	26
178	Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. Diagnostic Microbiology and Infectious Disease, 2019, 95, 114856.	0.8	25
179	Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens â€“ The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study . Infection and Drug Resistance, 2019, Volume 12, 3607-3623.	1.1	25
180	PME-1, an Extended-Spectrum Î²-Lactamase Identified in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2011, 55, 2710-2713.	1.4	24

#	Article	IF	Citations
181	Aliphatic Halogenase Enables Lateâ€Stage Câ^'H Functionalization: Selective Synthesis of a Brominated Fischerindole Alkaloid with Enhanced Antibacterial Activity. ChemBioChem, 2016, 17, 466-470.	1.3	24
182	Hospital Readmissions in Patients With Carbapenem-ResistantKlebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2016, 37, 281-288.	1.0	24
183	High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium. Emerging Infectious Diseases, 2017, 23, 1902-1904.	2.0	23
184	Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria. Bioorganic and Medicinal Chemistry, 2017, 25, 5749-5753.	1.4	22
185	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2017, 4, ofx157.	0.4	22
186	Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1779-1785.	1.3	22
187	Synthesis of calcitonin gene-related peptide (CGRP) by rat arterial endothelial cells. Histology and Histopathology, 2001, 16, 1073-9.	0.5	22
188	Outbreak ofKlebsiella pneumoniaeCarbapenemaseâ€"ProducingCitrobacter freundiiat a Tertiary Acute Care Facility in Miami, Florida. Infection Control and Hospital Epidemiology, 2017, 38, 320-326.	1.0	21
189	A Prospective Study of Acinetobacter baumannii Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids. Journal of Clinical Microbiology, 2019, 57, .	1.8	21
190	Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades. Journal of Clinical Microbiology, 2020, 58, .	1.8	21
191	KPC Type B-Lactamase, Rural Pennsylvania. Emerging Infectious Diseases, 2006, 12, 1613-1614.	2.0	20
192	Increase in number of Weibel-Palade bodies and endothelin-1 release from endothelial cells in the cadmium-treated rat thoracic aorta. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1996, 428, 367-73.	1.4	19
193	Safety and Efficacy of Long-Term Outpatient Ertapenem Therapy. Antimicrobial Agents and Chemotherapy, 2014, 58, 3437-3440.	1.4	19
194	The Bartonella autotransporter BafA activates the host VEGF pathway to drive angiogenesis. Nature Communications, 2020, 11, 3571.	5.8	19
195	CTX-M as the predominant extended-spectrum Â-lactamases among Enterobacteriaceae in Manila, Philippines. Journal of Antimicrobial Chemotherapy, 2010, 65, 584-586.	1.3	18
196	Economic Impact of Acinetobacter baumannii Infection in the Intensive Care Unit. Infection Control and Hospital Epidemiology, 2010, 31, 1087-1089.	1.0	18
197	Sequence Type ST405Escherichia coliIsolate Producing QepA1, CTX-M-15, and RmtB from Detroit, Michigan. Antimicrobial Agents and Chemotherapy, 2011, 55, 3966-3967.	1.4	18
198	Contamination of Ambient Air with Acinetobacter baumannii on Consecutive Inpatient Days. Journal of Clinical Microbiology, 2015, 53, 2346-2348.	1.8	18

#	Article	IF	Citations
199	Inhibition of Fosfomycin Resistance Protein FosA by Phosphonoformate (Foscarnet) in Multidrug-Resistant Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	18
200	Prevalence of Extended-Spectrum Î²-Lactamases CTX-M-8 and CTX-M-2-Producing Salmonella Serotypes from Clinical and Nonhuman Isolates in Brazil. Microbial Drug Resistance, 2017, 23, 580-589.	0.9	18
201	Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	18
202	Contribution of the TetB Efflux Pump to Minocycline Susceptibility among Carbapenem-Resistant Acinetobacter baumannii Strains. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	18
203	Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I). Open Forum Infectious Diseases, 2022, 9, ofab616.	0.4	18
204	Histamine release from Weibel-Palade bodies of toad aortas induced by endothelin-1 and sarafotoxin-S6b. The Anatomical Record, 1995, 242, 374-382.	2.3	17
205	KPC-Producing Klebsiella pneumoniae Strains That Harbor AAC(6â€²)-Ib Exhibit Intermediate Resistance to Amikacin. Antimicrobial Agents and Chemotherapy, 2014, 58, 7597-7600.	1.4	17
206	In Vivo Evolution of CMY-2 to CMY-33 Î²-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2015, 59, 7483-7488.	1.4	17
207	Use of online tools for antimicrobial resistance prediction by whole-genome sequencing in methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Journal of Global Antimicrobial Resistance, 2019, 19, 136-143.	0.9	17
208	Lack of Seasonality in the Occurrence of Multidrug-Resistant Acinectobacter baumannii Complex. Infection Control and Hospital Epidemiology, 2012, 33, 1051-1052.	1.0	16
209	Complete Sequence of Conjugative IncA/C Plasmid Encoding CMY-2 Î²-Lactamase and RmtE 16S rRNA Methyltransferase. Antimicrobial Agents and Chemotherapy, 2015, 59, 4360-4361.	1.4	16
210	OXA-48-Producing Enterobacteriaceae Causing Bacteremia, United Arab Emirates. International Journal of Infectious Diseases, 2015, 30, 36-37.	1.5	16
211	Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol. Expert Review of Anti-Infective Therapy, 2022, 20, 1077-1094.	2.0	16
212	Genetic Environment of 16S rRNA Methylase Gene rmtD. Antimicrobial Agents and Chemotherapy, 2008, 52, 2270-2272.	1.4	15
213	Escherichia colisequence type 131: epidemiology and challenges in treatment. Expert Review of Anti-Infective Therapy, 2014, 12, 597-609.	2.0	15
214	Complete Sequence of a Conjugative IncN Plasmid HarboringblaKPC-2,blaSHV-12, andqnrS1from an Escherichia coli Sequence Type 648 Strain. Antimicrobial Agents and Chemotherapy, 2014, 58, 6974-6977.	1.4	15
215	Emergence of CMY-2-Producing Salmonella Heidelberg Associated with IncI1 Plasmids Isolated from Poultry in Brazil. Microbial Drug Resistance, 2019, 25, 271-276.	0.9	15
216	Elastase Activity From Pseudomonas aeruginosa Respiratory Isolates and ICU Mortality. Chest, 2021, 160, 1624-1633.	0.4	15

#	Article	IF	Citations
217	Moesin Is Not a Receptor for Measles Virus Entry into Mouse Embryonic Stem Cells. Journal of Virology, 1998, 72, 1586-1592.	1.5	15
218	New Delhi Metallo-Î²-Lactamase-1â€“ProducingKlebsiella pneumoniae, Florida, USA1. Emerging Infectious Diseases, 2016, 22, 744-746.	2.0	14
219	IncX2 and IncX1-X2 Hybrid Plasmids Coexisting in a FosA6-Producing Escherichia coli Strain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
220	MCR-1-dependent lipid remodelling compromises the viability of Gram-negative bacteria. Emerging Microbes and Infections, 2022, 11, 1236-1249.	3.0	14
221	16S ribosomal RNA methylase RmtD produced by Klebsiella pneumoniae in Brazil. Journal of Antimicrobial Chemotherapy, 2008, 61, 746-747.	1.3	13
222	Economic value of Acinetobacter baumannii screening in the intensive care unit. Clinical Microbiology and Infection, 2011, 17, 1691-1697.	2.8	13
223	Escherichia coli Sequence Type 354 Coproducing CMY-2 Cephalosporinase and RmtE 16S rRNA Methyltransferase. Antimicrobial Agents and Chemotherapy, 2014, 58, 4246-4247.	1.4	13
224	Penicillins and Î²-Lactamase Inhibitors. , 2015, , 263-277.e3.		13
225	Clostridioides difficile: a potential source of NpmA in the clinical environment. Journal of Antimicrobial Chemotherapy, 2019, 74, 521-523.	1.3	13
226	Characterization of a Novel IncHI2 Plasmid Carrying Tandem Copies of bla _{CTX-M-2} in a fosA6 -Harboring Escherichia coli Sequence Type 410 Strain. Antimicrobial Agents and Chemotherapy, 2016, 60, 6742-6747.	1.4	12
227	Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Journal of Clinical Microbiology, 2016, 54, 791-794.	1.8	12
228	CXC Chemokines Exhibit Bactericidal Activity against Multidrug-Resistant Gram-Negative Pathogens. MBio, 2017, 8, .	1.8	12
229	Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii. Journal of Infection and Chemotherapy, 2019, 25, 681-686.	0.8	12
230	Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri. Antimicrobial Agents and Chemotherapy, 2021, 65, e0015021.	1.4	12
231	A New TEM-Derived Extended-Spectrum Î²-Lactamase (TEM-91) with an R164C Substitution at the Î©-Loop Confers Ceftazidime Resistance. Antimicrobial Agents and Chemotherapy, 2003, 47, 2981-2983.	1.4	11
232	Comparison of Minocycline Susceptibility Testing Methods for Carbapenem-Resistant Acinetobacter baumannii. Journal of Clinical Microbiology, 2016, 54, 2937-2941.	1.8	11
233	Diversity of High-Level Aminoglycoside Resistance Mechanisms among Gram-Negative Nosocomial Pathogens in Brazil. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
234	Evolution of Sequence Type 4821 Clonal Complex Meningococcal Strains in China from Prequinolone to Quinolone Era, 1972â€“2013. Emerging Infectious Diseases, 2018, 24, 683-690.	2.0	11

#	Article	IF	Citations
235	High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	11
236	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, ofy351.	0.4	11
237	Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	11
238	Variability in oral antibiotic step-down therapy in the management of Gram-negative bloodstream infections. International Journal of Antimicrobial Agents, 2021, 58, 106451.	1.1	11
239	Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. Japanese Journal of Radiology, 2022, 40, 800-813.	1.0	11
240	Expression of Î±-calcitonin gene-related peptide in the enteric nervous system of rat small intestine. Neuroscience Letters, 2000, 285, 33-36.	1.0	10
241	Escherichia coliProducing CMY-2 Î²-Lactamase in Retail Chicken, Pittsburgh, Pennsylvania, USA. Emerging Infectious Diseases, 2012, 18, 515-516.	2.0	10
242	Klebsiella pneumoniae Sequence Type 11 Isolate Producing RmtG 16S rRNA Methyltransferase from a Patient in Miami, Florida. Antimicrobial Agents and Chemotherapy, 2014, 58, 4980-4981.	1.4	10
243	Comment on: Resistance gene naming and numbering: is it a new gene or not?. Journal of Antimicrobial Chemotherapy, 2016, 71, 2677-2678.	1.3	10
244	Molecular epidemiology and spatiotemporal analysis of hospital-acquired Acinetobacter baumannii infection in a tertiary care hospital in southern Thailand. Journal of Hospital Infection, 2017, 95, 53-58.	1.4	10
245	Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection. BMC Emergency Medicine, 2017, 17, 25.	0.7	10
246	ORF-based binarized structure network analysis of plasmids (OSNAp), a novel approach to core gene-independent plasmid phylogeny. Plasmid, 2020, 108, 102477.	0.4	10
247	Genomic patterns and characterizations of chromosomally-encoded mcr-1 in Escherichia coli populations. Gut Pathogens, 2020, 12, 55.	1.6	10
248	Ampicillin-Ceftriaxone vs Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Scoreâ€“Matched, Retrospective Cohort Analysis. Open Forum Infectious Diseases, 2021, 8, ofab102.	0.4	10
249	Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus. Clinical Infectious Diseases, 2022, 74, 2067-2076.	2.9	10
250	Enhanced expression of endothelin-1 and endothelin-converting enzyme-1 in acute hypoxic rat aorta. Histology and Histopathology, 2002, 17, 97-105.	0.5	10
251	Complete Sequences of Multidrug Resistance Plasmids BearingrmtD1andrmtD216S rRNA Methyltransferase Genes. Antimicrobial Agents and Chemotherapy, 2016, 60, 1928-1931.	1.4	9
252	Functional and Structural Characterization of Acquired 16S rRNA Methyltransferase NpmB1 Conferring Pan-Aminoglycoside Resistance. Antimicrobial Agents and Chemotherapy, 2021, 65, e0100921.	1.4	9

#	Article	IF	Citations
253	A Novel Lipid-Based MALDI-TOF Assay for the Rapid Detection of Colistin-Resistant Enterobacter Species. Microbiology Spectrum, 2022, 10, e0144521.	1.2	9
254	Molecular Features of Community-Associated Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli Strains in the United States. Antimicrobial Agents and Chemotherapy, 2014, 58, 6953-6957.	1.4	8
255	Comparative Genome Analysis of Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli Sequence Type 131 Strains from Nepal and Japan. MSphere, 2016, 1, .	1.3	8
256	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	1.1	8
257	Rapid diagnostic testing for antimicrobial stewardship: Utility in Asia Pacific. Infection Control and Hospital Epidemiology, 2021, 42, 864-868.	1.0	8
258	Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum Î²-lactamase-producing Escherichia coli. Journal of Infection and Chemotherapy, 2021, 27, 1602-1606.	0.8	8
259	Other Î²-Lactam Antibiotics. , 2015, , 293-297.e2.		8
260	Vasocontractions of the in-vitro toad aortas induced by endothelin-1 and sarafotoxin-S6b. The Anatomical Record, 1993, 235, 253-260.	2.3	7
261	Chromosomal 16S Ribosomal RNA Methyltransferase RmtE1 in Escherichia coli Sequence Type 448. Emerging Infectious Diseases, 2000, 23, 876-878.	2.0	7
262	Faropenem Disks for Screening of Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae: TABLE 1. Journal of Clinical Microbiology, 2014, 52, 3501-3502.	1.8	7
263	Screening for Methicillin-Resistant Staphylococcus aureus Colonization Using Sponges. Infection Control and Hospital Epidemiology, 2015, 36, 28-33.	1.0	7
264	Carriage of Î²-lactamase-producing Enterobacteriaceae by Chinese travellers. Lancet Infectious Diseases, The, 2017, 17, 138-139.	4.6	7
265	Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases, 2021, 73, 730-739.	2.9	7
266	Structure of AmpC Î²-lactamase (AmpCD) from anEscherichia coliclinical isolate with a tripeptide deletion (Gly286-Ser287-Asp288) in the H10 helix. Acta Crystallographica Section F: Structural Biology Communications, 2009, 65, 540-543.	0.7	6
267	Optimal Therapy for Multidrug-ResistantAcinetobacter baumannii. Emerging Infectious Diseases, 2010, 16, 171-171.	2.0	6
268	CHARACTERIZATION OF KLEBSIELLA PNEUMONIAE AND ESCHERICHIA COLI STRAINS THAT PRODUCE CTX-M-2-TYPE BROAD SPECTRUM BETA-LACTAMASE ISOLATED FROM A CHILD WITH LEUKEMIA. Pediatric Infectious Disease Journal, 2002, 21, 260-262.	1.1	6
269	Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients. International Journal of Infectious Diseases, 2022, 115, 218-223.	1.5	6
270	Transmission of NDM-5-Producing and OXA-48-Producing Escherichia coli Sequence Type 648 by International Visitors without Previous Medical Exposure. Microbiology Spectrum, 2021, 9, e0182721.	1.2	6

#	Article	IF	Citations
271	In Vitro Global Surveillance of Eravacycline and Comparators Against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, Including Multidrug-Resistant (MDR) Isolates, Over a 3-Year Period (2013â€“2015). Open Forum Infectious Diseases, 2016, 3, .	0.4	5
272	In VitroActivity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains. Antimicrobial Agents and Chemotherapy, 2016, 60, 5101-5101.	1.4	5
273	Disposable Bronchoscope Model for Simulating Endoscopic Reprocessing and Surveillance Cultures. Infection Control and Hospital Epidemiology, 2017, 38, 136-142.	1.0	5
274	Plasmid Carrying bla CTX-M-2 and bla GES-1 in Extensively Drug-Resistant Pseudomonas aeruginosa from Cerebrospinal Fluid. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	5
275	Use of a cohorting-unit and systematic surveillance cultures to control a Klebsiella pneumoniae carbapenemase (KPC)â€“producing Enterobacteriaceae outbreak. Infection Control and Hospital Epidemiology, 2019, 40, 767-773.	1.0	5
276	Left ventricular assist device-associated endocarditis involving multiple clones of Staphylococcus aureus with distinct antimicrobial susceptibility patterns. International Journal of Infectious Diseases, 2019, 84, 44-47.	1.5	5
277	Polymyxin Resistance in Klebsiella pneumoniae: Complexity at Every Level. Clinical Infectious Diseases, 2020, 70, 2092-2094.	2.9	5
278	OXA-23 and OXA-40 producing carbapenem-resistant Acinetobacter baumannii in Central Illinois. Diagnostic Microbiology and Infectious Disease, 2020, 97, 114999.	0.8	5
279	PhaseÂII Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. Infectious Diseases and Therapy, 2021, 10, 2353-2369.	1.8	5
280	Delayed Injection Site Reaction After mRNA-1273 Vaccination in Japan: A Retrospective, Cross-Sectional Study. Open Forum Infectious Diseases, 2021, 8, ofab497.	0.4	5
281	Effectiveness of Favipiravir on Nonsevere, Early-Stage COVID-19 in Japan: A Large Observational Study Using the COVID-19 Registry Japan. Infectious Diseases and Therapy, 2022, 11, 1075-1087.	1.8	5
282	CTX-M-35 extended-spectrum Î²-lactamase conferring ceftazidime resistance in Citrobacter koseri. International Journal of Antimicrobial Agents, 2010, 35, 412-413.	1.1	4
283	Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. Open Forum Infectious Diseases, 2017, 4, ofx216.	0.4	4
284	In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum Î²-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
285	Duration of carbapenemase-producing Enterobacteriales carriage among ICU patients in Miami, FL: A retrospective cohort study. American Journal of Infection Control, 2021, 49, 1281-1286.	1.1	4
286	Epidemiology of carbapenem-resistant Enterobacteriaceae in hospitals of a large healthcare system in Miami, Florida from 2012 to 2016: Five years of experience with an internal registry. American Journal of Infection Control, 2020, 48, 1341-1347.	1.1	4
287	Natural History of Multidrug-Resistant Acinetobacter baumannii Carriage in Intensive Care Units. Infection Control and Hospital Epidemiology, 2012, 33, 642-643.	1.0	4
288	The Passenger Domain of Bartonella bacilliformis BafA Promotes Endothelial Cell Angiogenesis via the VEGF Receptor Signaling Pathway. MSphere, 2022, 7, e0008122.	1.3	4

#	Article	IF	Citations
289	Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae, Northeast Florida. Southern Medical Journal, 2009, 102, 680-687.	0.3	3
290	In Vitro Global Surveillance of Eravacycline and Comparators Against Staphylococcus spp. and Enterococcus spp. Over a 3-Year Period (2013â€“2015). Open Forum Infectious Diseases, 2016, 3, .	0.4	3
291	Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258. Journal of Antimicrobial Chemotherapy, 2019, 74, 2203-2208.	1.3	3
292	Evaluation of the Accelerate Pheno System for Identification of Acinetobacter Clinical Isolates and Minocycline Susceptibility Testing. Journal of Clinical Microbiology, 2019, 57, .	1.8	3
293	Insights on Coronavirus Disease 2019 Epidemiology From a Historic Cruise Ship Quarantine. Clinical Infectious Diseases, 2021, 72, e458-e459.	2.9	3
294	Comparison of sCIM and Other Phenotypic Detection Methods for Carbapenemase-Producing Enterobacterales. Microbiology Spectrum, 2021, 9, e0160821.	1.2	3
295	Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections. JAC-Antimicrobial Resistance, 2021, 4, dlac005.	0.9	3
296	Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum Î²-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function. Antibiotics, 2022, 11, 456.	1.5	3
297	Prediction of Antibiotic Resistance Evolution by Growth Measurement of All Proximal Mutants of Beta-Lactamase. Molecular Biology and Evolution, 2022, 39, .	3.5	3
298	Rational Framework for the Design of Trp- and Arg-Rich Peptide Antibiotics Against Multidrug-Resistant Bacteria. Frontiers in Microbiology, 2022, 13, .	1.5	3
299	Reply to Falagas and Karageorgopoulos. Clinical Infectious Diseases, 2008, 46, 1122-1123.	2.9	2
300	Ceftazidimeâ€“avibactam Susceptibility Patterns in Carbapenem-Resistant Enterobacteriaceae in the USA: Results from the Consortium on Resistance against Carbapenems in Klebsiella and Other Enterobacteriaceae (CRACKLE-2). Open Forum Infectious Diseases, 2017, 4, S133-S134.	0.4	2
301	Draft Genome Sequences of bla KPC -Containing Enterobacter aerogenes, Citrobacter freundii, and Citrobacter koseri Strains. Genome Announcements, 2018, 6, .	0.8	2
302	636. Genome Epidemiology of Carbapenem-Resistant Acinetobacter baumannii (CRAb) in the United States. Open Forum Infectious Diseases, 2019, 6, S295-S295.	0.4	2
303	Outcomes of Adjunctive Therapy with Intravenous Cefoperazone-Sulbactam for Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Acinetobacter baumannii. Infection and Drug Resistance, 2021, Volume 14, 1255-1264.	1.1	2
304	The authors reply. Critical Care Medicine, 2013, 41, e480-e481.	0.4	1
305	2438. Ceftolozane/Tazobactam (C/T) Against Multidrug-Resistant Pseudomonas aeruginosa (MDR-Pa) Infections: Clinical Efficacy, and Baseline and Emergent Resistance. Open Forum Infectious Diseases, 2018, 5, S729-S729.	0.4	1
306	485. Clinical and Molecular Epidemiology of Carbapenem Non-susceptible Citrobacter sp.. Open Forum Infectious Diseases, 2019, 6, S237-S238.	0.4	1

#	Article	IF	Citations
307	Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort. Journal of Infection and Chemotherapy, 2021, 27, 1350-1356.	0.8	1
308	Extensively drug-resistant IMP-16-producing Pseudomonas monteilii isolated from cerebrospinal fluid. Infection, Genetics and Evolution, 2021, 87, 104658.	1.0	1
309	Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates. Phage, 2022, 3, 50-58.	0.8	1
310	Infections with Organisms Producing Extended-Spectrum Î²-Lactamase. Issues in Infectious Diseases, 2010, , 21-34.	0.1	0
311	32: The Presence of an 11,111 m/z Peak in the Mass Spectrum of Escherichia coli Is Suggestive of Klebsiella pneumoniae Carbapenemase-Mediated Carbapenem Resistance. American Journal of Clinical Pathology, 2015, 143, A016-A016.	0.4	0
312	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle). Open Forum Infectious Diseases, 2016, 3, .	0.4	0
313	Reply to Iwata: Are all fosfomycins alike? Reply to author. Journal of Infection and Chemotherapy, 2016, 22, 725.	0.8	0
314	1180. Addition of Chronic Kidney Disease Status to Pitt Bacteremia Score Improves Prediction of Mortality in Patients With Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infectious Diseases, 2018, 5, S356-S357.	0.4	0
315	2065. Whole Genome Sequencing for Antimicrobial Resistance Prediction in MRSA and VRE: A Real-world Application. Open Forum Infectious Diseases, 2018, 5, S603-S603.	0.4	0
316	Absence of fosfomycin resistance in gastrointestinal Escherichia coli following fosfomycin therapy. Journal of Global Antimicrobial Resistance, 2018, 14, 109-110.	0.9	0
317	508. Gentamicin Non-susceptibility is Associated with Persistence of Carbapenem-Resistant Klebsiella pneumoniae in the Urinary Tract. Open Forum Infectious Diseases, 2019, 6, S246-S246.	0.4	0
318	622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS). Open Forum Infectious Diseases, 2019, 6, S289-S289.	0.4	0
319	The Elucidation of Pathogenicity of Carbapenemase-Producing Klebsiella Pneumoniae Pulmonary Infection Using Single Cell RNAseq. , 2019, , .		0
320	630. Clinical and Molecular Characteristics of Carbapenem-Resistant Enterobacteriaceae in Qatar: A Retrospective and Prospective Observational Study. Open Forum Infectious Diseases, 2019, 6, S292-S292.	0.4	0
321	2282. Empiric Antimicrobial Therapy and Clinical Outcomes of Infections due to ESBL-producing Klebsiella pneumoniae. Open Forum Infectious Diseases, 2019, 6, S781-S782.	0.4	0
322	605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidimeâ€“Avibactam Resistance. Open Forum Infectious Diseases, 2019, 6, S283-S283.	0.4	0
323	Pseudomonas Aeruginosa Protease and Elastase Activity Are Common in ICU Respiratory Isolates. , 2019, , .		0
324	Pathogenicity of mcr-1-positive Escherichia coli from human infections. Lancet Microbe, The, 2020, 1, e195.	3.4	0

#	Article	IF	Citations
325	Increased Alternative Complement Pathway Function Improves Survival During Critical Illness. , 2020, , .		0
326	Pseudomonas Aeruginosa Protease and Elastase Activity Are Associated with Increased 30-Day Mortality in ICU Patients. , 2020, , .		0
327	Global Spread of Multidrug-Resistant Gram-Negative Bacilli. , 0, , 213-222.		0
328	Risk factors for the development of infections associated with carbapenemase-producing Enterobacteriaceae among previously colonized patients: A retrospective cohort study. Infection Control and Hospital Epidemiology, 2021, 42, 1-4.	1.0	0
329	Dissecting the clonality of I1 plasmids using ORF-based binarized structure network analysis of plasmids (OSNAp). Journal of Infection and Chemotherapy, 2022, 28, 473-479.	0.8	0